Scholarlink

Purpose <p>Elderly breast cancer (BC) patients are commonly at risk of under-treatment, which can negatively affect their prognosis. Therefore, we analyzed age-related survival differences considering clinico-pathological parameters among patients with early BC.</p> Methods <p>8190 BC patients from SUCCESS A, B, and C trials who underwent surgery and adjuvant systemic therapy were analyzed. Tumor and nodal stage, grading, biological subtype, types of surgical and systemic therapies, and other clinico-pathological parameters were compared between age groups ≤ 50&#xa0;years, 51–65&#xa0;years, &gt; 65&#xa0;years (chi-square tests). Breast cancer-free interval (BCFI), breast cancer-specific survival (BCSS), overall survival (OS), invasive disease-free survival (iDFS), and distant disease-free survival (DDFS) were analyzed using univariable and adjusted multivariable Cox regression models. Two-way interactions between age and other clinico-pathological parameters were calculated.</p> Results <p>There were significant differences between the age groups concerning almost all parameters analyzed, especially more advanced tumor stages in the elderly group. Univariable analysis showed significant differences between the age groups for all survival parameters (all <i>p &lt; </i>0.001). However, after adjustment for other prognostic parameters, an independent significant age effect was found only for iDFS (<i>p = </i>0.038), while there was no significant independent age effect on BCFI (<i>p = </i>0.286), BCSS (<i>p = </i>0.981), OS (<i>p = </i>0.131) and DDFS (<i>p = </i>0.316).</p> Conclusion <p>Although elderly BC patients &gt; 65&#xa0;years had poorer survival, multivariable analysis suggests this difference is mostly attributable to advanced tumor stages rather than age itself. Effective BC screening and research related to the influence of (biological) age on response to cancer therapies could be the next step to improve understanding the relationship between patient age and BC survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-dependent differences in survival of patients with early breast cancer: analysis of SUCCESS A, B, C trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月19日

查看全文
  • Stefan Lukac,
  • Davut Dayan,
  • Wolfgang Janni,
  • Brigitte Rack,
  • Visnja Fink,
  • Kristina Veselinovic,
  • Kerstin Pfister,
  • Angelina Fink,
  • Thomas W. P. Friedl,
  • Elena Leinert

摘要

Purpose

Elderly breast cancer (BC) patients are commonly at risk of under-treatment, which can negatively affect their prognosis. Therefore, we analyzed age-related survival differences considering clinico-pathological parameters among patients with early BC.

Methods

8190 BC patients from SUCCESS A, B, and C trials who underwent surgery and adjuvant systemic therapy were analyzed. Tumor and nodal stage, grading, biological subtype, types of surgical and systemic therapies, and other clinico-pathological parameters were compared between age groups ≤ 50 years, 51–65 years, > 65 years (chi-square tests). Breast cancer-free interval (BCFI), breast cancer-specific survival (BCSS), overall survival (OS), invasive disease-free survival (iDFS), and distant disease-free survival (DDFS) were analyzed using univariable and adjusted multivariable Cox regression models. Two-way interactions between age and other clinico-pathological parameters were calculated.

Results

There were significant differences between the age groups concerning almost all parameters analyzed, especially more advanced tumor stages in the elderly group. Univariable analysis showed significant differences between the age groups for all survival parameters (all p < 0.001). However, after adjustment for other prognostic parameters, an independent significant age effect was found only for iDFS (p = 0.038), while there was no significant independent age effect on BCFI (p = 0.286), BCSS (p = 0.981), OS (p = 0.131) and DDFS (p = 0.316).

Conclusion

Although elderly BC patients > 65 years had poorer survival, multivariable analysis suggests this difference is mostly attributable to advanced tumor stages rather than age itself. Effective BC screening and research related to the influence of (biological) age on response to cancer therapies could be the next step to improve understanding the relationship between patient age and BC survival.